Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) will likely be posting its quarterly earnings results before the market opens on Thursday, February 20th. Analysts expect Aurinia Pharmaceuticals to post earnings of $0.04 per share and revenue of $59.94 million for the quarter.
Aurinia Pharmaceuticals Price Performance
Shares of NASDAQ:AUPH opened at $7.79 on Tuesday. The company has a 50-day simple moving average of $8.47 and a 200-day simple moving average of $7.66. Aurinia Pharmaceuticals has a one year low of $4.71 and a one year high of $10.67. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of -51.93 and a beta of 1.22.
Wall Street Analyst Weigh In
Separately, StockNews.com cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, February 10th.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Further Reading
- Five stocks we like better than Aurinia Pharmaceuticals
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Airbnb’s Earnings: Sky High Results, Grounded Guidance?
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Kyndryl Soars on AI, Cybersecurity Growth—What’s Next?
- Investing in Travel Stocks Benefits
- Conflicting Signals: Tempus AI’s Stock Market Rally
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.